{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:50Z","timestamp":1785168290555,"version":"3.55.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0169444","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T18:49:56Z","timestamp":1484938196000},"page":"e0169444","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1371","volume":"12","author":[{"given":"Tongjing","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maocong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1002\/hep.20956","article-title":"Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005","volume":"43","author":"HJ Yim","year":"2006","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jhep.2010.12.042","article-title":"The hepatitis B e antigen (HbeAg) targets and suppress activation of the toll-like receptor signaling pathway","volume":"55","author":"T Lang","year":"2011","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B","volume":"3","author":"YF Liaw","year":"2009","journal-title":"Hepatol Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/17474124.2015.960398","article-title":"Improving clinical outcomes of chronic hepatitis B virus infection","volume":"9","author":"TH Su","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1440-1746.2011.06940.x","article-title":"Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection","volume":"27","author":"Z Zhang","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guideline for treatment of chronic hepatitis B","volume":"63","author":"NA Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","year":"2016","journal-title":"Hepatol Int"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","article-title":"Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B","volume":"3","author":"H Dakin","year":"2010","journal-title":"Value Health"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/phar.1188","article-title":"Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis","volume":"33","author":"A Wiens","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivu dine for HBeAg-positive chronic hepatitis B","volume":"354","author":"TT Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"ref14","first-page":"891","article-title":"A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B","volume":"45","author":"GB Yao","year":"2006","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial","volume":"47","author":"J Hou","year":"2008","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis b","volume":"357","author":"CL Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis b","volume":"359","author":"P Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S695","DOI":"10.1016\/S0016-5085(12)62685-7","article-title":"Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis b patients: A randomized controlled trial","volume":"142","author":"T Sriprayoon","year":"2012","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jvh.12313","article-title":"Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial","volume":"22","author":"JL Hou","year":"2015","journal-title":"J Viral Hepat"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"P Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"ref21","first-page":"387","article-title":"Adefovir dipivovil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China","volume":"23","author":"MD Zeng","year":"2006","journal-title":"China J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"RG Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12072-008-9088-8","article-title":"Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-na\u00efve Chinese patients with chronic hepatitis B: A randomized, multicenter study","volume":"2","author":"GB Yao","year":"2008","journal-title":"Hepatology International"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12072-013-9488-2","article-title":"Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients","volume":"8","author":"JD Jia","year":"2014","journal-title":"Hepatology International"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"YF Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"ref26","first-page":"27","article-title":"A comparison of treatment with adefovir and entecavir for chronic hepatitis b in china: the 2-year results of a prospective study: adefovir versus entercavir for chronic hepatitis b","volume":"11","author":"EQ Chen","year":"2011","journal-title":"Hepat Mon"},{"key":"ref27","article-title":"Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B(study 103), preliminary analysis","volume":"48","author":"EJ Heathcote","year":"2008","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"NW Leung","year":"2001","journal-title":"Hepatology"},{"key":"ref29","first-page":"346","article-title":"Three year adefovir dipivoxil treatment for hepatitis b e antigen-positive chronic hepatitis b patients","volume":"15","author":"N Ling","year":"2007","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1478-3231.2011.02490.x","article-title":"Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B","volume":"31","author":"EJ Gane","year":"2011","journal-title":"Liver Int"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2893.2010.01271.x","article-title":"Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients","volume":"17","author":"GB Yao","year":"2010","journal-title":"Journal of Viral Hepatitis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1016\/S0016-5085(15)31685-1","article-title":"A randomized controlled trials to compare the efficacy and safety of entecavir versus tenofovir treatment in na\u00efve chronic hepatitis b patients","volume":"148","author":"T Sriprayoon","year":"2015","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"EJ Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","article-title":"Four years of lamivudine treatment in Chinese patients with chronic hepatitis B","volume":"19","author":"TT Chang","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"ref35","first-page":"384","article-title":"A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years","volume":"25","author":"JY Liang","year":"2011","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","article-title":"Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B","volume":"20","author":"Y Wang","year":"2013","journal-title":"J Viral Hepat"},{"key":"ref37","first-page":"S195","article-title":"Effect of telbivudine and entecavir on HBeAg positive chronie hepatitis B: A 4-year follow-up","volume":"7","author":"X Chen","year":"2013","journal-title":"Hepatology International"},{"key":"ref38","article-title":"Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B(Study 103)","volume":"52","author":"EJ Heathcote","year":"2010","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1751-2980.2009.00375.x","article-title":"A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China","volume":"10","author":"GB Yao","year":"2009","journal-title":"Journal of Digestive Diseases"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1478-3231.2011.02641.x","article-title":"Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B","volume":"32","author":"Z Minde","year":"2012","journal-title":"Liver International"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"287.e1","DOI":"10.1016\/j.cmi.2015.10.024","article-title":"A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China","volume":"22","author":"Y Zhang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"TT Chang","year":"2010","journal-title":"Hepatology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"P Marcellin","year":"2013","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2011.04.008","article-title":"Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B","volume":"91","author":"Y Chen","year":"2011","journal-title":"Antiviral Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"A Bertoletti","year":"2012","journal-title":"Gut"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"9486","DOI":"10.3748\/wjg.v20.i28.9486","article-title":"Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B","volume":"20","author":"CZ Li","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/jvh.12059","article-title":"Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients","volume":"20","author":"GQ Wang","year":"2013","journal-title":"J Viral Hepat"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MAJ.0b013e318286878d","article-title":"Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis","volume":"347","author":"H Liu","year":"2014","journal-title":"Am J Med Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2046-4053-3-21","article-title":"The importance of baseline viral load when assessing relative efficacy in treatment-na\u00efve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis","volume":"3","author":"S Mealing","year":"2014","journal-title":"Syst Rev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gut.52.3.416","article-title":"A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy","volume":"52","author":"MF Yuen","year":"2003","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"C Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"ref52","unstructured":"Wu YK, Lin GL, Li XY, Chen SR, Yang FJ, Ao YL, et al. (2014) 6 years retrospective and prospective real world research on efficacy and safety of initial treatment with nucleos (t) ide analogues in patients with chronic HBV infection. The Thirteenth National infectious disease academic conference proceedings. Guangzhou, China."},{"key":"ref53","doi-asserted-by":"crossref","first-page":"95.e1","DOI":"10.1016\/j.cmi.2015.05.035","article-title":"Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience","volume":"22","author":"MC Tsai","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"ref54","first-page":"173","article-title":"Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors","volume":"28","author":"H Kranidioti","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase","volume":"52","author":"AB van Nunen","year":"2003","journal-title":"Gut"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis Be antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"JG Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","volume":"35","author":"C Ferrari","year":"2015","journal-title":"Liver Int"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"C Boni","year":"2003","journal-title":"J Hepatol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1086\/516538","article-title":"Spontaneous seroconversion in hepatitis B e Antigen-positive chronic hepatitis B: implications for interferon therapy","volume":"176","author":"AA Evans","year":"1997","journal-title":"The Journal of Infectious Disease"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0169444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T23:28:37Z","timestamp":1719012517000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169444"}},"subtitle":[],"editor":[{"given":"Ferruccio","family":"Bonino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0169444","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}